The medication is commonly used for conditions presenting with systemic imbalance, specifically those related to heightened androgen activity in women. It is generally used to help with symptoms that interfere with daily functioning.

Relief for Pronounced Androgen-Driven Conditions

This medication is relevant for easing symptom clusters that may become intense or disruptive, particularly severe skin manifestations. It helps address severe acne, is considered relevant in situations where symptoms may intensify temporarily, and may assist with managing excessive oiliness (seborrhea). The supportive relief generally assists with managing these pronounced symptoms and contributes to improved day-to-day comfort.

Ginette is applied across domains where additional symptomatic support is needed to address excessive hair growth (hirsutism), and it supports the management of symptoms related to menstrual cycle regularity in conditions such as Polycystic Ovary Syndrome (PCOS). This medication is relevant for managing these androgen-dependent symptoms, including severe acne, hirsutism, and seborrhea, and is applied when consideration of reproductive planning is also appropriate.

Therapeutic Context
Main Use Context	Hyperandrogenic skin conditions and hormonal imbalance
Key Symptom Groups	Severe acne, hirsutism, irregular menstrual cycles
Benefit	Contributes to functional stability and assists with easing symptomatic burden
Context	Applied when systemic management is appropriate

Regulatory References

1. European Medicines Agency (EMA) on Cyproterone Acetate/Ethinylestradiol

Who can and cannot use Ginette?

The population eligibility for Ginette (Cyproterone Acetate/Ethinyl Estradiol) is strictly defined by regulatory authorities and is generally restricted to women of childbearing age. The medicine is officially indicated for the treatment of moderate to severe androgen-sensitive conditions only after failure of prior treatments, such as topical therapy or systemic antibiotics, and must not be used solely for contraception.

Contraindications and Restrictions

Official labeling outlines several absolute contraindications where the medicine must not be used, primarily concerning risks of thrombosis and malignancy:

Category	Regulatory Status
Vascular History	Contraindicated in presence or history of Venous or Arterial Thromboembolism (VTE/ATE) or known thrombogenic mutations.
Malignancy/Liver	Contraindicated in severe hepatic disease, liver tumours, and known or suspected hormone-sensitive malignancies (e.g., breast cancer).
Pregnancy/Lactation	Contraindicated in known or suspected pregnancy and during the period of breastfeeding.
Combined Risk	Contraindicated in women over 35 years old who are also smokers.
Duration of Use	Use is strictly limited and should be discontinued 3 to 4 cycles after the treated condition has completely resolved.

Use is also prohibited in patients with migraine with focal neurological symptoms or history of meningioma. The medicine is not recommended before menarche or after menopause.

Interactions with other medicines and products

The interaction profile of Ginette (Cyproterone Acetate/Ethinyl Estradiol) is defined by mandatory restrictions and pharmacokinetic interactions that alter drug exposure, as stated in regulatory documents.

Formally Contraindicated Combinations

Co-administration with specific antiviral combination regimens for Hepatitis C (HCV) is formally prohibited. This restriction applies to regimens containing ombitasvir/paritaprevir/ritonavir pm dasabuvir, as well as combinations containing glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir. This classification is based on the documented risk of increased Alanine Aminotransferase (ALT) enzyme levels.

Pharmacokinetic Interactions (Exposure Changes)

The primary interaction mechanism is the alteration of hormone clearance via the CYP450 enzyme system, specifically CYP3A4.

• Exposure Reduction (Risk of Efficacy Loss): Substances that induce the CYP3A4 enzyme reduce the plasma concentration of both Cyproterone Acetate and Ethinyl Estradiol. Explicitly listed enzyme inducers include certain anticonvulsants (e.g., phenytoin, carbamazepine), antibacterials (e.g., rifampicin), and the herbal product St. John's Wort (Hypericum perforatum).
• Altered Concentration of Co-administered Drugs: Ginette can inhibit the metabolism of certain other medicines, which may lead to an increased plasma concentration of the co-administered drug, such as Tizanidine, or a decreased concentration of drugs like Lamotrigine.

Pharmacodynamic Restrictions

Regulatory information states that Ginette must not be used concurrently with any other hormonal contraceptive product (including other pills, patches, or rings). Furthermore, the Ethinyl Estradiol component may decrease the therapeutic efficacy of antidiabetic agents.

Ginette's mechanism of action involves the synergistic activity of two hormonal components: cyproterone acetate (CPA) and ethinylestradiol (EE).

Cyproterone acetate functions as an androgen receptor antagonist, competitively binding to androgen receptors in target cells, particularly those in the skin and hair follicles, thereby inhibiting the physiological action of endogenous androgens like testosterone and dihydrotestosterone. CPA also exhibits a progestogenic effect, which contributes to the compound’s overall antigonadotropic activity. This activity suppresses the release of luteinizing hormone (LH) and, to a lesser extent, follicle-stimulating hormone (FSH) from the pituitary gland.

Ethinylestradiol, a synthetic estrogen, serves as an estrogen receptor agonist. Its primary contribution is the augmentation of the antigonadotropic effect, further suppressing ovarian androgen secretion. Additionally, EE stimulates the hepatic synthesis of Sex Hormone-Binding Globulin (SHBG). The increase in circulating SHBG concentration leads to enhanced binding of endogenous androgens, effectively decreasing the fraction of free, biologically active androgens in the plasma. The combined result is a significant reduction in overall androgenic stimulation at the cellular level and a suppression of ovarian function.

How to Use Ginette: Administration Guidelines

Ginette is a fixed-dose hormonal combination product administered via the oral route, supplied as a film-coated tablet. The primary usage pattern follows a cyclic schedule designed to maintain consistent hormonal regulation throughout the treatment course. This regimen reflects the standardized use of the combined components.

---

Standard Dosing and Administration Schedule

Administration involves taking one tablet daily according to a prescribed 28-day cycle. Each tablet contains a standardized dose of Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.035 mg.

The full 28-day sequence comprises:

• Active Dosing: 21 consecutive days of taking the active tablet.
• Tablet-Free Interval: Followed by 7 days during which no tablets are taken.

To ensure proper initiation of the hormonal course, the first tablet of the first pack is started on Day 1 of the menstrual cycle (the first day of menstrual bleeding).

Procedural Administration Rules

The tablet should be swallowed whole with a small amount of water; it should not be crushed or chewed. It is required that the tablet be taken at approximately the same time each day to maintain the stability of the systemic hormonal levels. Specific instructions are provided for managing a missed dose, with the procedural steps depending on the elapsed time and the current week of the treatment cycle.

Course Duration and Population

The treatment is structured as a continuation of these defined, repeating cycles for as long as the systemic effects of the regimen are necessary. The usage is confined to women of reproductive age, as the product is not indicated for use in post-menopausal women.

Research Evidence Overview of Studies for Ginette

The clinical evaluation of Ginette, a combination of Cyproterone Acetate and Ethinyl Estradiol, has been described through numerous official and peer-reviewed studies, including randomized controlled trials (RCTs), systematic reviews, and long-term observational research. The evidence contributes to the broader scientific landscape by outlining the types of studies that exist for symptoms linked to elevated androgen activity with this specific hormonal combination.

---

Evidence for Use in Moderate to Severe Acne and Seborrhea

Research has explored the use of this combination in women of reproductive age who have been diagnosed with moderate to severe acne that was observed in contexts related to androgen sensitivity, which can also include excessive oiliness or seborrhea. The studies conducted often employed controlled trial designs where the combination was evaluated in comparison to other active agents or combined oral contraceptives. The primary measures researchers monitored were changes in the physical presentation of acne, specifically looking at counts of lesions and overall global assessments of severity made by investigators.

---

Evidence for Use in Hirsutism (Excessive Hair Growth)

The evidence base for hirsutism, which is excessive and unwanted hair growth, includes Randomized Controlled Trials and long-term observational studies; these are relevant in trials assessing symptoms that change slowly over time. Outcomes were measured using validated tools such as the Ferriman-Gallwey (F-G) score to quantify hair growth changes. Because hair growth is a slow process, research explored symptom patterns and monitored responses over defined time intervals, with the observed changes typically reported after six months or longer.

---

What is Still Uncertain About Ginette Research

While the evidence contributes to the broader evidence landscape, sample sizes were modest in some of the older comparative trials, which means that direct comparisons against all newer treatment alternatives may have limited certainty. Evidence quality varies across studies due to the lack of standardized assessment tools in earlier research. The research provides context but not individual predictions, and long-term effects are not fully established for all endpoints, particularly concerning the non-androgen-related metabolic features of Polycystic Ovary Syndrome (PCOS), where data remain insufficient. Findings describe group patterns, not personal outcomes.

Key Studies & References Diane-35, 0.035 mg/2 mg coated tablets - Summary of Product Characteristics (European regulatory information)

Common questions about Ginette (FAQ)

---

Q: What is the difference between Ginette and other common acne treatments?

Ginette is a systemic, fixed-dose hormonal combination that provides strong anti-androgen action, which targets the hormonal cause of acne. Official regulatory indications state that this medicine is typically reserved for moderate to severe acne only after other local treatments, such as topical creams or oral antibiotics, have proven unsuccessful.

---

Q: Why do doctors prescribe Ginette for conditions other than just acne?

Studies and official information indicate that Ginette is also indicated for the treatment of hirsutism, which is excessive and unwanted hair growth in women. It is used to address other physical manifestations of hormonal imbalance associated with elevated male-type hormones (androgens).

---

Q: Can taking Ginette cause spotting or breakthrough bleeding?

As with many hormonal contraceptives, the official product information for Ginette often includes menstrual changes like spotting (light bleeding outside the regular period) and breakthrough bleeding among the possible side effects. If this experience is persistent or concerning, discussing it with a healthcare provider is recommended.

---

Q: Is it normal to feel nauseous when you first start taking Ginette?

According to official safety documents, nausea is listed as a common side effect of Ginette, meaning it may affect between 1 in 100 to 1 in 10 users. This effect may improve as the body adjusts to the hormonal components, but individual experiences vary.

---

Q: Can men use Ginette for any condition, like hair loss?

Official regulatory documents strictly restrict the use of Ginette. The medicine is indicated and studied only for use in women of reproductive age.

---

Q: How long does Ginette typically stay in your system after you stop taking it?

Official pharmacokinetic information indicates that the active hormonal components, Cyproterone Acetate and Ethinyl Estradiol, are eliminated from the body in two phases. The final elimination half-lives of both components generally last about 1 to 2 days, and they are mainly excreted through urine and bile.

---

Q: Does Ginette have an effect on your libido?

Changes in libido (sex drive), which can be either decreased or increased, are listed in official safety documents as a rare side effect. This means they are expected to affect fewer than 1 in 1,000 users.

---

Q: Is it safe to drink alcohol in moderation while using Ginette?

The official product information does not list alcohol as a formal contraindication or a substance that compromises the medication's effectiveness through a direct drug interaction. Specific advice regarding alcohol consumption while taking this medication is best obtained from a healthcare professional.

---

Q: Does Ginette improve or worsen oily hair and scalp?

Ginette is indicated for conditions related to excessive androgen activity, including severe acne and seborrhea (excessive oiliness). The treatment is specifically intended to improve these conditions by reducing androgen effects on the skin and hair follicles.

---

Q: How soon after stopping Ginette can you try to conceive?

When Ginette is stopped, the menstrual cycle and fertility typically return to the pattern the individual had before starting treatment. Conception rates observed in studies with similar hormonal combinations generally return to normal within the first few cycles after discontinuation.

---

Q: What is the difference in active ingredients between Ginette and Diane-35?

Ginette and Diane-35 are simply different brand names used in various countries for the exact same fixed-dose combination hormonal product. Both contain the active ingredients Cyproterone Acetate and Ethinyl Estradiol at the same specific dosage.

---

Q: Do studies show Ginette is more effective for severe or mild acne?

Official indications and studies show that Ginette is specifically intended for and evaluated in the treatment of moderate to severe acne. This implies it is typically reserved for more pronounced or persistent cases related to hormonal imbalance.

---

Q: Does Ginette protect against sexually transmitted infections (STIs)?

No. Official regulatory documents clearly state that hormonal contraceptives, including Ginette, provide no protection against HIV/AIDS or any other sexually transmitted infections.

---

Q: Are the side effects of Ginette the same for everyone?

No. Official safety documents categorize side effects by frequency (e.g., Common, Uncommon, Rare) because individuals will react differently to the medication. It is expected that most users will not experience all listed side effects, especially those classified as rare.

---

Q: Do proton pump inhibitors (PPIs) affect the absorption of Ginette?

The product information focuses on specific enzyme inducers, like certain anticonvulsants, as the main drugs that can reduce Ginette's hormone concentration. While PPIs are not explicitly listed, the label warns about any interaction that could lower the hormone levels and potentially reduce efficacy.

---

Q: Is there a generic version of Ginette?

Ginette is a specific brand name. However, equivalent products containing the same dose and combination of Cyproterone Acetate and Ethinyl Estradiol are widely available under various generic and alternative brand names across different regions.

---

Q: How does Ginette influence the production of androgens in the body?

The hormonal combination suppresses the release of certain pituitary hormones (LH and FSH), which in turn suppresses the activity of the ovaries. This suppression of ovarian function leads to a reduction in the body's overall secretion of ovarian androgens (male hormones).

---

Q: What clinical trials have been conducted on Ginette?

The efficacy and safety of Ginette are supported by clinical evidence, including randomized controlled trials (RCTs) and long-term observational studies. These trials compared the combination against other active treatments for conditions linked to androgen sensitivity.

---

Q: Can sunlight exposure be a problem while taking Ginette?

Similar hormonal products sometimes list skin side effects like chloasma (pigmentation patches) in official documents. This condition is known to be aggravated by exposure to sunlight. For specific concerns about sun exposure while using this medicine, consult the official product information or a healthcare provider.

---

Q: Why is Ginette not recommended for long-term use in some cases?

Regulatory information strictly limits the duration of use. The medication must be discontinued 3 to 4 cycles after the treated condition is resolved due to rare but serious risks, particularly the elevated risk of venous thromboembolism (VTE), or blood clots.

---

Q: Does Ginette affect liver function tests?

Yes, official regulatory warnings indicate that Ginette is contraindicated in severe hepatic (liver) disease. The product label also warns that combining it with specific Hepatitis C antiviral regimens is prohibited due to the documented risk of increasing Alanine Aminotransferase (ALT) enzyme levels.

---

Q: Is it true that Ginette can help with excessive facial hair?

Yes. Ginette is officially indicated for the treatment of hirsutism, which is the medical term for excessive and unwanted hair growth, including growth in androgen-sensitive areas like the face.

---

Q: What is the risk of ovarian cysts while on Ginette?

Since Ginette contains hormonal components that suppress ovulation, it is expected to suppress the physiological process that leads to the formation of functional ovarian cysts.

---

Q: Are there any specific tests I need to have before starting Ginette?

Official guidelines recommend that before initiating treatment, an appropriate medical examination, including a gynecological check, should be performed. The patient's full medical history should be evaluated, and pregnancy and certain blood clotting disorders should be formally excluded.

---

Q: Why do some people experience breast tenderness when starting Ginette?

Breast pain or tenderness is listed as a common side effect in official documents. This is typically attributed to the hormonal components (Ethinyl Estradiol and Cyproterone Acetate) affecting the sensitive tissues in the breast.

---

Q: Does Ginette affect cholesterol levels or blood pressure?

Yes, official regulatory warnings indicate that the medication may cause changes in lipid parameters (such as cholesterol and triglyceride levels). High blood pressure (hypertension) is also listed as a possible side effect and a pre-existing condition that requires careful assessment.

---

Q: What is the typical duration of treatment with Ginette for acne?

Studies and official information show that visible improvement in acne symptoms usually requires at least three months of continuous treatment. Doctors typically assess the need for continuation at the three-to-six-month mark and periodically after that.

Ginette (cyproterone acetate and ethinylestradiol) must be stored under specific environmental and temperature conditions to ensure its stability.

Storage Requirements

Labeled Storage Temperature:	Must be stored at a temperature not exceeding 30 C.
:---	:---
Protection Requirements:	Must be kept protected from light and away from moisture and heat.
Packaging Rule:	Must be stored in the original container (e.g., blister pack and carton).
Child-Safety Rule:	Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Ginette tablets must be disposed of according to local regulations for pharmaceutical waste. Formal drug take-back programs are the preferred method. If no take-back program is available, the medicine should be mixed with an undesirable substance, placed in a sealed bag, and discarded in the household trash to prevent accidental exposure.